Introduction to Animal Models of Liver Failure

Acute liver failure is a syndrome characterized by diffuse hepatocellular necrosis and/or abrupt, severe impairment of hepatic function, with a mortality rate that can exceed 75%. Its etiology is primarily attributable to viral hepatitis; it may also result from single or repeated traumatic injury, or from excessive exposure to drugs or toxins. Currently, mice and rats are commonly used to establish animal models of acute liver failure suitable for research purposes. Following model induction, these animals exhibit pathological features such as hepatocellular necrosis, elevated liver enzymes, jaundice, ascites, and impaired hepatic metabolism and coagulation, thereby closely mimicking the clinical manifestations of acute liver failure.

Service Advantages of the Aniphe BioLablogical Animal Model Platform for Liver Failure

Aniphe BioLab possesses extensive expertise in establishing liver disease models and a robust pharmacological efficacy evaluation system, enabling it to provide clients with high‑quality animal models of hepatic failure.

	High modeling success rate Standardized operating procedures ensure excellent model reproducibility and consistency.
	The testing system has been improved. Supports multi-dimensional assessments, including serum biochemistry, pathology, and inflammatory cytokines.
	Comprehensive efficacy evaluation It is suitable for research on hepatoprotective, anti-inflammatory, antioxidant, and liver‑regenerative drugs.
	Supports customized services Modeling protocols and assessment metrics can be designed according to research requirements.
	One-stop technology platform Providing end-to-end services, including model development, pharmacological efficacy evaluation, and mechanistic studies.

Modeling cycle	1–4 weeks
Laboratory animals	Rodents, rabbits, dogs, pigs
Positive drug	N-acetylcysteine (NAC) is commonly used as a positive control drug, capable of alleviating hepatocellular injury, reducing serum transaminase levels, and improving oxidative stress and liver function parameters.
Application areas	This model is widely employed in studies of the pathogenic mechanisms underlying acute liver injury and liver failure, in investigations into the mechanisms of inflammation and oxidative stress, in research on hepatocyte protection and regeneration, and in the evaluation of the efficacy and mechanisms of action of hepatoprotective agents, anti-inflammatory drugs, natural products, biologics, and innovative therapeutics.

Construction of an Animal Model of Liver Failure

It is possible to establish mainstream models such as hepatic ischemia-reperfusion injury, partial hepatectomy–induced liver regeneration, and liver failure. Ischemia-reperfusion injury can be induced by occluding hepatic blood flow, or a liver lobe resection can be performed to create the model. Following surgery, animals exhibit extensive hepatocellular necrosis and marked elevations in serum transaminases and other liver enzymes, accompanied by jaundice, ascites, and other overt clinical signs. Hepatic metabolism and coagulation function are significantly impaired, comprehensively replicating the typical pathological features of acute liver failure seen in clinical practice.

Model features:

The model features a short replication cycle, quantifiable liver resection, and no specific pathological changes in the residual liver tissue. The animals’ clinical signs and corresponding alterations in blood biomarkers are consistent with the clinical manifestations of hepatic failure. Moreover, the model exhibits good reproducibility and stability, with a high success rate, making it currently the most ideal surgical model.